Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Revenue projections:

Revenue projections for SPARC
Revenue projections for SPARC

Revenues for SPARC are expected to rise beyond last year's, potentially signaling a worthwhile investment opportunity. Investors may find the growth compelling if it aligns with other positive fundamentals, as it suggests the company is performing well and may offer good returns on investment.

Financial Ratios:

currentRatio 0.02900
forwardPE 0.00000
debtToEquity 0.00000
earningsGrowth 0.00000
revenueGrowth -0.38900
grossMargins 0.52027
operatingMargins -8.68702
trailingEps -8.24000
forwardEps 55.40000

SPARC's current ratio of 0.029 indicates that the company's cash reserves and current assets may not fully cover its short-term debts. This suggests potential liquidity risks and may require SPARC to find alternative solutions to meet its near-term obligations.
SPARC's low growth in earnings and revenue indicates a potential decline in profits. This suggests that the company could be facing financial challenges, making it harder to sustain its current profit margins.

Price projections:

Price projections for SPARC
Price projections for SPARC